With Phase III Failure, Exelixis Drops First-Line Liver Cancer Plans For Cabometyx

 
• By Joseph Haas
Exelixis needs new strategy
Exelixis needs a new strategy in first-line liver cancer after Phase III miss • Source: Alamy

More from Clinical Trials

More from R&D